6th ICHNO Abstract Book

page 70 6 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 16 – 18 March 2017 Barcelona, Spain __________________________________________________________________________________________ randomized trial with a large sample size should be conducted to confirm our results. 6th ICHNO

male and 30/96 (31%) were ≥80 years old. The primary tumour location was larynx 63 (66%), pharynx 12 (13%), oral cavity 11 (12%), other 10 (9%). Breakdown of TNM stage were: T1 29 (30%), T2 15 (16%), T3 23 (24%), T4 29 (30%), N0 69 (72%), N1 11 (12%), N2 13 (14%), N3 3 (2%). Surgery involved in 25 (26%) patients followed by adjuvant RT. Curative RT was delivered to 61/96 (64%) patients with median 66 (range 62-70) Gy and palliative RT were to 10/96 (10%) patients with median and 30 (range 30-39) Gy. 2D conventional, 3D conformal technique and IMRT were used in 11 (12%), 60 (62%) and 25 (26%) patients respectively. Concurrent platinum chemotherapy was given to 6 (6%) of patients. Acute toxicity was seen in 86 (90%) patients (grade-1 75%, grade-2 10%, grade-3 5%). Median 3 (range 1-10) days off in the treatment in 61 (64%) patients. 82/96 (85%) patients completed their RT scheme without any interruption. 71 (74%) patients experienced complete response. 1 and 2 years DFS for the all cohort was 61% and 56%, and OS was 84% and 78%, respectively. Radiotherapy technique did not significantly affect the survival. In univariate analysis, gender (female, p=0.01), advanced T stage (T2-4, p=0.001) and N stage (N2-3, p=0.003) for DFS, and older age (≥80 years, p=0.008), and advanced N stage (N2-3, p=0,01) for OS had found the negative impact (Figure 1). Stage 2-4 disease was found a poor prognostic factor for DFS in multivariate analysis (p<0,05, Exp(β)=0,190, 95% CI for Exp(β)=0,065-0,556). Conclusion Radiotherapy provides high rates of tumor control and survival with reasonable toxicity, although the very low concurrent chemotherapy usage in elderly patients aged ≥70 with HNSCC. Radiotherapy requires careful schedule selection and follow-up in elderly patients aged ≥ 80 years. PO-147 The ELAN program: Customised treatment of SCCHN elderly patients according to geriatric assessment J. Guigay (France), C. Ortholan, H. Le Caer, S. Renard- oldrini, X. Sun, L. Mayache-badis, L. Geoffrois, J. Fayette, C. Even, D. Vansteene, Y. Pointreau, D. Schwob, N. Vintonenko, C. Michel, J. Bourhis, A. Auperin, C. Mertens 1 Centre Antoine Lacassagne, Medical Oncology, Nice, France 2 Princesse Grace Hospital, Radiotherapy, Monaco, Monaco 3 Centre Hospitalier de la Dracénie, Medical Oncology, Draguignan, France 4 Institut de Cancérologie de Lorraine, Radiotherapy, Vandoeuvre-lès-Nancy, France 5 CHBM Site du Mittan, Radiotherapy, Montbéliard, France 6 Gustave Roussy, Medical Oncology, Villejuif, France 7 Institut de Cancérologie de Lorraine, Medical Oncology, Vandoeuvre-lès-Nancy, France 8 Centre Léon Bérard, Medical Oncology, Lyon, France 9 Institut de Cancérologie de l’Ouest René Gauducheau, Medical Oncology, Nantes, France 10 Clinique Victor Hugo, Medical Oncology, Le Mans, France 11 Gustave Roussy, Datamanagement, Villejuif, France 12 GORTEC, Clinical Research, Tours, France 13 GORTEC, Clinical Research, Nice, France 14 GORTEC, Radiotherapy, Tours, France 15 Gustave Roussy, Biostatistics, Villejuif, France 16 Institut Bergonié, Geriatry, Bordeaux, France Purpose or Objective Thirty percent of SCCHN occur in patients (pts) more than 70y; the main challenge in these pts is to balance the benefit/risk treatment ratio regarding tumor related symptoms. However, these pts are usually excluded from

PO-146 Radiotherapy in elderly patients aged ≥ 70 years with head and neck squamous cell carcinoma E. Metcalfe 1 , D. Etiz 1 , A. Ozen 1 1 Osmangazi University Medical Faculty, Radiation Oncology, Eskisehir, Turkey Purpose or Objective To review survival outcomes and analyse the treatment tolerance in elderly patients aged ≥ 70 years with head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy (RT). Material and Methods Patients aged ≥ 70 years treated with radiotherapy between 2005-2016 for HNSCC were retrospectively identified. 2D conventional and 3D conformal radiotherapy technique was used until 2015, and subsequently patients were treated with IMRT. Outcome measures were 1 and 2 year disease free survival (DFS), and overall survival (OS). Univariate and multivariate analyses was performed for survival outcomes.

Results

A total of 96 consecutive ≥70 years and patients were identified. Median follow up was 26 (range 3-125) months. Median age was 78 years (range 70-97). 77/96 (80%) were